Mersana Therapeutics, Inc.
MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.41
Price+4.60%
$0.37
1Y
Price
Market Cap
$41.972m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-763.6%
EBITDA Margin-795.0%
Net Profit Margin-739.6%
Free Cash Flow MarginRevenue
$34.769m
-14.1%
1y CAGR+11.5%
3y CAGR+15437.7%
5y CAGREarnings
-$74.037m
-7.0%
1y CAGR+23.3%
3y CAGR+11.8%
5y CAGREPS
-$14.92
-5.7%
1y CAGR+29.4%
3y CAGR+24.5%
5y CAGRBook Value
-$53.146m
$84.573m
Assets$137.719m
Liabilities$20.621m
DebtDebt to Assets
24.4%
-0.3x
Debt to EBITDAFree Cash Flow
-$79.756m
+3.3%
1y CAGR-58.9%
3y CAGR-28.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company